Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Breast Cancer

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CBC.2008.n.019PMID 18621615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2023cited by this paper
• Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression.

  2006cited by this paper
• Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer.

  2006cited by this paper
• Gemcitabine plus carboplatin for patients with pretreated, metastatic breast cancer: A phase II trial.

  2006cited by this paper
• Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

  2005cited by this paper
• Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience

  2005cited by this paper
• Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.

  2004cited by this paper
• Efficacy and Safety of Trastuzumab as a Single Agent in Heavily Pretreated Patients with Her-2/NEU-Overexpressing Metastatic Breast Cancer

  2004cited by this paper
• Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.

  2004cited by this paper
• Gemcitabine plus carboplatin in recurrent and advanced breast cancer: A phase II trial

  2004cited by this paper
• Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.

  2004cited by this paper
• Caring for heavily pretreated patients with metastatic breast cancer (MBC): Carboplatin (CBDCA) - gemcitabine (GCB) combination is effective and well tolerate.

  2004cited by this paper
• Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.

  2004cited by this paper
• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  2004cited by this paper
• Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.

  2004cited by this paper
• Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

  2003cited by this paper
• Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.

  2003cited by this paper
• Gemcitabine and trastuzumab in metastatic breast cancer.

  2003cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer.

  2002cited by this paper
• Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

  2002cited by this paper
• Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.

  2002cited by this paper
• Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

  2002cited by this paper
• Oklahoma City ­ OK!

  2002cited by this paper
• First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

  2001cited by this paper
• Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

  1997cited by this paper
• Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes.

  1989cited by this paper
• The wolf in the cello

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer

  2024cites this paper
• Liver X receptors induce antiproliferative effects in basal‐like breast cancer

  2023cites this paper
• Triple-Negative Breast Cancer

  2018cites this paper
• Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

  2018cites this paper
• Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

  2018cites this paper
• Pharmacometabonomics Analysis Reveals Serum Formate and Acetate Potentially Associated with Varying Response to Gemcitabine-Carboplatin Chemotherapy in Metastatic Breast Cancer Patients.

  2018cites this paper
• Management of Metastatic Triple-Negative Breast Cancer

  2018cites this paper
• Individualizing the Approach to the Older Woman with Triple-Negative Breast Cancer

  2018cites this paper
• Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2‐neu Negative and Triple Negative Metastatic Breast Cancer

  2017cites this paper
• Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.

  2016cites this paper
• Heat Shock Protein-Based Therapies

  2015influential citation
• TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

  2015cites this paper
• Treating Triple-Negative Breast Cancer: Where Are We?

  2015cites this paper
• Heat Shock Proteins in Triple-Negative Breast Cancer (TNBC) Treatment

  2015cites this paper
• Estudio de adecuación de la prescripción de quimioterapia en cáncer de mama en un hospital de tercer nivel

  2014cites this paper
• Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

  2014cites this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cites this paper
• Indications et gestion des effets secondaires

  2013cites this paper
• Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

  2013cites this paper
• Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

  2013cites this paper
• Appraising iniparib, the PARP inhibitor that never was—what must we learn?

  2013cites this paper
• Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

  2013cites this paper
• Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review

  2013cites this paper
• Recent Progress in Metastatic Breast Cancer : Focus on Cytotoxic Therapy Medical Experts :

  2013cites this paper
• A CME-CERTIFIED ACTIVITY Recent Progress in Metastatic Breast Cancer: Focus on Cytotoxic Therapy

  2013cites this paper
• Prerequisite Genetic Traits for Metastasis

  2013cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• Targeting triple-negative breast cancer: optimising therapeutic outcomes.

  2012cites this paper
• Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs

  2012cites this paper
• Chemotherapy Options for Metastatic HER2-Negative Breast Cancer after Prior Exposure to Anthracyclines and Taxanes

  2012cites this paper
• Systematic Phenotypic Screening for Novel Synergistic Combinations: A New Paradigm for Repositioning Existing Drugs

  2012cites this paper
• What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

  2012cites this paper
• Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer

  2011cites this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cites this paper
• Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif

  2011cites this paper
• Leczenie interferujące z funkcją EGFR u chorych na raka piersi

  2011cites this paper
• The therapy interfering EGFR activation in breast cancer patients

  2011cites this paper
• Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

  2011cites this paper
• Stratégies thérapeutiques des cancers métastatiques RH+, HER2+ : trastuzumab, chimiothérapie, hormonothérapie

  2010cites this paper
• Triple-Negative Breast Cancer: Unique Biology and Its Management

  2010cites this paper
• [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

  2010cites this paper
• Triple-negative breast cancer: novel therapies and new directions.

  2009cites this paper
• A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

  2009cites this paper
• 2008 Publications of the Baylor Health Care System Medical and Scientific Staff

  2009cites this paper
• A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.

  2008cites this paper
• Metastatic breast cancer: the treatment challenge.

  2008cites this paper